Dynavax Technologies CORP 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Dynavax Technologies Corporation has completed its merger with Sanofi, becoming an indirect wholly-owned subsidiary, with shares acquired at $15.50 per share.
Sanofi announced an agreement to acquire Dynavax Technologies Corporation for $15.50 per share in cash, a 39% premium, adding a marketed adult hepatitis B vaccine and a shingles candidate to its portfolio.
Dynavax Technologies Corporation reported strong third-quarter 2025 financial results, including a 13% increase in HEPLISAV-B revenue, and authorized a new $100 million share repurchase program.
Dynavax Technologies Corporation announced a management realignment, transitioning David F. Novack and removing Robert Janssen, M.D. from his roles.
Dynavax Technologies Corporation announced positive topline results from Part 1 of its Phase 1/2 clinical trial for Z-1018, its novel shingles vaccine candidate, demonstrating comparable immunogenicity and a favorable tolerability profile against Shingrix.
Dynavax Technologies Corporation announced record second quarter 2025 financial results, driven by strong HEPLISAV-B vaccine sales and positive pipeline advancements.
Dynavax Technologies Corporation announced that its stockholders approved a phased declassification of the board of directors and re-elected the company's nominated Class I directors, while rejecting a dissident shareholder proposal, at its 2025 Annual Meeting.
Dynavax Technologies Corporation appoints Joseph Metzinger as its Vice President, Chief Accounting Officer, effective May 12, 2025.
Dynavax Technologies Corporation announced its first quarter 2025 financial results, highlighted by a 36% year-over-year increase in HEPLISAV-B net product revenue and the advancement of new vaccine programs.
Dynavax Technologies completed a private offering of $225 million in convertible senior notes due 2030, using proceeds to exchange existing 2026 notes and repurchase shares.
Dynavax Technologies Corporation has entered into agreements to issue $225 million in new convertible senior notes due 2030, using proceeds to exchange existing 2026 notes and for general corporate purposes.
Dynavax Technologies Corporation announces a 26% year-over-year increase in HEPLISAV-B net product revenue for 2024, reaching $268 million, and projects further growth in 2025.
Dynavax addresses Deep Track Capital's nomination of board candidates, emphasizing its commitment to long-term stockholder value and defending its strategic plan.
Dynavax Technologies Corporation has entered into a new supply agreement with West Pharmaceutical Services for syringe stoppers and appointed Kelly MacDonald as the principal accounting officer.
Justin Burgess, Dynavax's principal accounting officer, will resign on or about March 3, 2025, with CFO Kelly MacDonald to assume the role.
Dynavax Technologies Corporation appoints Lauren Silvernail and Emilio Emini to its Board of Directors, while Peggy V. Phillips and Julie Eastland will retire and resign, respectively, effective prior to the 2025 Annual Meeting.
Dynavax reports a 26% year-over-year increase in HEPLISAV-B net product revenue for 2024, reaching approximately $268 million, and advances its clinical pipeline.
Dynavax Technologies Corporation has amended its Rights Agreement to grant its Board of Directors greater authority in administering the agreement.
Dynavax Technologies has entered into an agreement with Goldman Sachs to repurchase $100 million of its common stock through an accelerated share repurchase program.
Dynavax Technologies Corporation announced strong third-quarter 2024 financial results, highlighted by a 27% year-over-year increase in HEPLISAV-B revenue and a $200 million share repurchase program.
Dynavax Technologies has adopted a limited-duration stockholder rights plan to protect against potential hostile takeovers following a significant stock accumulation by Deep Track Capital.
Dynavax Technologies Corporation announced record quarterly revenue for its HEPLISAV-B vaccine and provided updates on its clinical pipeline, including the initiation of a Phase 1/2 trial for a novel shingles vaccine.
Dynavax Technologies Corporation has reappointed Kelly MacDonald as Chief Financial Officer, effective August 1, 2024, following her maternity leave.
Dynavax Technologies' stockholders approved an increase in shares for the equity incentive plan and elected three Class III directors at their 2024 annual meeting.
Dynavax Technologies Corporation announced a 10% year-over-year increase in HEPLISAV-B vaccine net product revenue for the first quarter of 2024, along with progress in its clinical pipeline.
Dynavax Technologies Corporation has appointed Ryan Spencer as Interim Chief Financial Officer while Kelly MacDonald is on maternity leave, effective April 1, 2024.
Dynavax Technologies has entered into a new sublease agreement with Metagenomi for its office/laboratory space, following the termination of the previous sublease with Zymergen due to bankruptcy.
Dynavax Technologies Corporation announced strong 2023 financial results driven by HEPLISAV-B sales growth and provided positive financial guidance for 2024, including expectations of being cash flow positive.